About this trial
A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of inability to deliver sufficient dose through external beam techniques. These patients respond well to re-irradiation using brachytherapy with about 50% of selected patients remaining free of recurrence 5 years after salvage. Advanced imaging using multiparametric Magnetic Resonance Imaging (mpMRI) allows identification of the site of recurrence, permitting partial prostate salvage brachytherapy. There is extensive literature on Low Dose Rate salvage brachytherapy but less on High Dose Rate.
Eligibility criteria
Qualifiers
Age >45 and Life expectancy >10 years
Previous External Beam Radiotherapy (EBRT) or LDR brachytherapy w
> 3 year interval since EBRT or LDR Brachytherapy
No late toxicity from prior EBRT ≥ grade 2
Disqualifiers
Not compliant with criteria above
Unable to give informed consent
Trial design
Treatments tested in this trial
- HDR partial prostate brachytherapy